NKGN
Income statement / Annual
Last year (2023), NKGen Biotech, Inc. Common Stock's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, NKGen Biotech, Inc. Common Stock's net income was -$82.95 M.
See NKGen Biotech, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$77,000.00 |
$426,000.00 |
| Cost of Revenue |
$1.20 M
|
$18,000.00
|
$30,000.00
|
| Gross Profit |
-$1.20 M
|
$59,000.00
|
$396,000.00
|
| Gross Profit Ratio |
0
|
0.77
|
0.93
|
| Research and Development Expenses |
$14.47 M
|
$16.75 M
|
$14.67 M
|
| General & Administrative Expenses |
$0.00
|
$7.66 M
|
$7.59 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.08 M
|
$7.66 M
|
$7.59 M
|
| Other Expenses |
$0.00
|
-$95,000.00
|
-$84,000.00
|
| Operating Expenses |
$28.54 M
|
$24.41 M
|
$22.26 M
|
| Cost And Expenses |
$29.75 M
|
$24.42 M
|
$22.29 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$745,000.00
|
$2.31 M
|
$1.32 M
|
| Depreciation & Amortization |
$1.20 M
|
$1.21 M
|
$1.24 M
|
| EBITDA |
-$28.54 M |
-$23.23 M |
-$20.70 M |
| EBITDA Ratio |
0
|
-301.7
|
-48.59
|
| Operating Income Ratio |
0
|
-316.18
|
-51.32
|
| Total Other Income/Expenses Net |
-$53.20 M
|
-$2.40 M
|
-$1.40 M
|
| Income Before Tax |
-$82.95 M
|
-$26.75 M
|
-$23.26 M
|
| Income Before Tax Ratio |
0
|
-347.36
|
-54.6
|
| Income Tax Expense |
$7,000.00
|
$7,000.00
|
$5,000.00
|
| Net Income |
-$82.95 M
|
-$26.75 M
|
-$23.27 M
|
| Net Income Ratio |
0
|
-347.45
|
-54.61
|
| EPS |
-5.38 |
-4.21 |
-1.08 |
| EPS Diluted |
-5.38 |
-4.21 |
-1.08 |
| Weighted Average Shares Out |
$15.43 M
|
$6.36 M
|
$21.45 M
|
| Weighted Average Shares Out Diluted |
$15.43 M
|
$6.36 M
|
$21.45 M
|
| Link |
|
|
|
